Aytu Biopharma (AYTU) Capital Expenditures (2015 - 2025)

Aytu Biopharma (AYTU) has reported Capital Expenditures for 8 consecutive years, with $17000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Capital Expenditures rose 183.33% year-over-year to $17000.0 in Q4 2025; TTM through Mar 2026 was $34000.0, a 93.7% decrease from a year earlier, with the FY2025 full-year figure at $228000.0, down 30.7% from the prior year.
• Capital Expenditures was $17000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $17000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $329000.0 in Q2 2024 and troughed at -$13.1 million in Q2 2021.
• A 3-year average of -$1.8 million and a median of $17000.0 in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures tumbled 123.21% in 2021 and surged 183.33% in 2025, its largest moves.
• Over 3 years, Capital Expenditures stood at -$13.1 million in 2021, then jumped by 100.05% to $6000.0 in 2024, then surged by 183.33% to $17000.0 in 2025.
• The last three Capital Expenditures figures came in at $17000.0 (Q4 2025), $17000.0 (Q2 2025), and $69000.0 (Q1 2025), per Business Quant data.